In our study we show that by leveraging the mTor dependency of HIF1-α, Temsirolimus suppresses the overshooting hypoxia response, reduces VEGF levels under normoxic and hypoxic conditions and inhibits tumor growth both in vitro and in vivo in KLF4-overexpressing tumor cells. Here, HIF1A is linked to neoplasm.